Cara Therapeutics reports the initiation of a Phase 2 trial of Oral KORSUVA (CR845/difelikefalin) for the treatment of pruritus in patients with hepatic impairment due to primary biliary cholangitis (PBC). Pruritus is a common symptom of cholestatic liver diseases with a prevalence of up to 70 percent in patients with PBC.
“We believe that Oral KORSUVA may provide a potential new, first-in-class therapeutic approach,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.